Account
Inquiry
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This innovative compound demonstrates significant potential in diabetes research by simultaneously targeting both receptor pathways to improve glycemic control.
The tirzepatide pens we supply contain pharmaceutical-grade material with purity exceeding 99%. The product appears as white to off-white powder or loose lumps and is packaged in sterile vials ranging from 5mg to 60mg concentrations to meet diverse research requirements.
Extensive clinical studies have shown tirzepatide's ability to effectively reduce HbA1c levels while promoting weight loss in test subjects. The dual agonist mechanism enhances insulin secretion while suppressing glucagon release in a glucose-dependent manner, making it particularly valuable for metabolic disorder research.
Our manufacturing process utilizes advanced chemical synthesis techniques to ensure batch-to-batch consistency. Each lot undergoes rigorous quality control testing to verify purity, potency, and stability. The tirzepatide pens are supplied with complete analytical documentation including HPLC and MS reports.
Important Note: This product is intended for laboratory research use only. Not for human consumption or diagnostic use. Researchers should handle all materials according to appropriate safety protocols and regulatory guidelines.
We offer flexible ordering options from small research quantities to bulk pharmaceutical supplies. Custom concentrations and packaging configurations are available for institutional and commercial research programs requiring tirzepatide pens in specific formats.
